Should I buy or sell Nautilus Biotechnology stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nautilus Biotechnology in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NAUT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NAUT, but not buy additional shares or sell existing shares. View NAUT analyst ratings or view top-rated stocks .

What is Nautilus Biotechnology's stock price target for 2024?

1 analysts have issued 1 year price objectives for Nautilus Biotechnology's stock. Their NAUT share price targets range from $6.00 to $6.00. On average, they expect the company's share price to reach $6.00 in the next year. This suggests a possible upside of 143.9% from the stock's current price. View analysts price targets for NAUT or view top-rated stocks among Wall Street analysts .

How have NAUT shares performed in 2024?

Nautilus Biotechnology's stock was trading at $2.99 at the start of the year. Since then, NAUT shares have decreased by 17.7% and is now trading at $2.46. View the best growth stocks for 2024 here .

When is Nautilus Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024. View our NAUT earnings forecast .

How can I listen to Nautilus Biotechnology's earnings call?

Nautilus Biotechnology will be holding an earnings conference call on Tuesday, April 30th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Nautilus Biotechnology's earnings last quarter?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.02. During the same quarter in the prior year, the company earned ($0.11) EPS.

How do I buy shares of Nautilus Biotechnology?

Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NAUT

Nautilus Biotechnology (NAUT) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free NAUT Stock Alerts

$2.46

+0.12 (+5.13%)

(As of 05:21 PM ET)

Compare

Today's Range: $2.31
▼
$2.46
50-Day Range: $2.34
▼
$3.06
52-Week Range: $2.16
▼
$4.65

Volume: 52,503 shs
Average Volume: 79,976 shs
Market Capitalization: $307.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Get Nautilus Biotechnology alerts:

Nautilus Biotechnology MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 143.9% Upside
$6.00 Price Target
Short Interest: Bearish
2.11% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$108,316 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.72) to ($0.82) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.67 out of 5 stars

Medical Sector

644th out of 911 stocks

Analytical Instruments Industry

23rd out of 26 stocks

3.0

Analyst's Opinion

Consensus Rating
Nautilus Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Nautilus Biotechnology has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.11% of the float of Nautilus Biotechnology has been sold short.
Short Interest Ratio / Days to Cover
Nautilus Biotechnology has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Nautilus Biotechnology has recently decreased by 2.44%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Nautilus Biotechnology does not currently pay a dividend.
Dividend Growth
Nautilus Biotechnology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NAUT.

2.0

News and Social Media Coverage

News Sentiment
Nautilus Biotechnology has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Nautilus Biotechnology this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for NAUT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Nautilus Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nautilus Biotechnology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $108,316.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
42.50% of the stock of Nautilus Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
50.71% of the stock of Nautilus Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Nautilus Biotechnology are expected to decrease in the coming year, from ($0.72) to ($0.82) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nautilus Biotechnology is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nautilus Biotechnology is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nautilus Biotechnology has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Nautilus Biotechnology Stock (NASDAQ:NAUT)

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

NAUT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NAUT Stock News Headlines

April 16, 2024 | morningstar.com

Nautilus Biotechnology Inc Ordinary Shares NAUT

April 11, 2024 | globenewswire.com

Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

March 12, 2024 | msn.com

Startup Mahakumbh Redefines India's Esports and Gaming Industry

March 11, 2024 | finance.yahoo.com

This Nautilus Biotechnology Insider Increased Their Holding In The Last Year

March 1, 2024 | seekingalpha.com

Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript

February 29, 2024 | finance.yahoo.com

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2023 Earnings Call Transcript

February 29, 2024 | finance.yahoo.com

Q4 2023 Nautilus Biotechnology Inc Earnings Call

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

February 28, 2024 | finance.yahoo.com

Nautilus Biotechnology Inc (NAUT) Reports Fiscal Year 2023 Financial Results

February 28, 2024 | globenewswire.com

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results

February 22, 2024 | globenewswire.com

Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference

February 15, 2024 | finance.yahoo.com

SkyWater Signs Production Agreement with Nautilus Biotechnology to Fabricate Novel Biomedical Devices

February 7, 2024 | msn.com

Will any Seattle startups go public this year? Analysts see better climate for tech IPOs

January 24, 2024 | finance.yahoo.com

With 33% ownership, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders have a lot at stake

January 8, 2024 | markets.businessinsider.com

NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates

December 14, 2023 | morningstar.com

Nautilus Biotechnology Inc Ordinary Shares

November 17, 2023 | msn.com

Startup tips from Isilon co-founder Sujal Patel on product-market fit, recruiting, hiring, scrappiness

November 17, 2023 | msn.com

Tech Moves: Icertis exec joins Zenoti; Brex names new president; Nautilus Biotechnology hires VP

November 3, 2023 | bizjournals.com

Daily Digest: Chase Center to host All-Star Game; Big CRE partnership ends

November 2, 2023 | es-us.finanzas.yahoo.com

Nautilus Biotechnology Inc (NAUT) Reports 21% Increase in Q3 2023 Operating Expenses

November 1, 2023 | insidermonkey.com

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2023 Earnings Call Transcript

October 31, 2023 | finanznachrichten.de

Nautilus Biotechnology Inc.: Nautilus Biotechnology Reports Third Quarter 2023 Financial Results

October 31, 2023 | msn.com

Nautilus Biotechnology GAAP EPS of -$0.13 misses by $0.01

October 25, 2023 | finance.yahoo.com

We're Hopeful That Nautilus Biotechnology (NASDAQ:NAUT) Will Use Its Cash Wisely

October 23, 2023 | msn.com

Nautilus Biotechnology: Trades At Net-Cash And Investment Value With Proteomics Upside

September 8, 2023 | wsj.com

Nautilus Biotechnology Inc.

See More Headlines

Receive NAUT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/19/2024
Next Earnings (Confirmed): 4/30/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Analytical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:NAUT
CUSIP: N/A
CIK: 1808805
Web: www.nautilus.bio
Phone: 206-333-2001
Fax: N/A
Employees: 167
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.00
High Stock Price Target: $6.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +147.9%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-63,670,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -22.42%
Return on Assets: -19.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 19.39
Quick Ratio: 19.39

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.12 per share
Price / Book: 1.14

Miscellaneous

Outstanding Shares: 125,100,000
Free Float: 71,931,000
Market Cap: $302.74 million
Optionable: Optionable
Beta: 1.20

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Sujal M. Patel (Age 49)
Co-Founder, CEO, President, Secretary & Director
Comp: $827.24k
Dr. Parag Mallick Ph.D. (Age 46)
Co-Founder, Chief Scientist & Director
Comp: $562.8k
Ms. Anna Mowry (Age 40)
CFO & Treasurer
Comp: $519.21k
Ms. Mary E. Godwin (Age 65)
Senior Vice President of Operations
Mr. Matthew B. Murphy ESQ. (Age 59)
General Counsel
Comp: $382.64k
Mr. Chris Blessington
Vice President of Corporate Marketing & Communications
Ms. Gwen E. Weld (Age 66)
Chief People Officer
Comp: $390.97k
Mr. Nick A. Nelson (Age 40)
Chief Business Officer & Senior VP of Business Development
Dr. Subra Sankar Ph.D. (Age 64)
Senior Vice President of Product Development
Comp: $38.47k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NAUT Stock Analysis - Frequently Asked Questions

Should I buy or sell Nautilus Biotechnology stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nautilus Biotechnology in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NAUT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NAUT, but not buy additional shares or sell existing shares.
View NAUT analyst ratings or view top-rated stocks.
What is Nautilus Biotechnology's stock price target for 2024?: 1 analysts have issued 1 year price objectives for Nautilus Biotechnology's stock. Their NAUT share price targets range from $6.00 to $6.00. On average, they expect the company's share price to reach $6.00 in the next year. This suggests a possible upside of 143.9% from the stock's current price.
View analysts price targets for NAUT or view top-rated stocks among Wall Street analysts.
How have NAUT shares performed in 2024?: Nautilus Biotechnology's stock was trading at $2.99 at the start of the year. Since then, NAUT shares have decreased by 17.7% and is now trading at $2.46.
View the best growth stocks for 2024 here.
When is Nautilus Biotechnology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our NAUT earnings forecast.

How can I listen to Nautilus Biotechnology's earnings call?: Nautilus Biotechnology will be holding an earnings conference call on Tuesday, April 30th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Nautilus Biotechnology's earnings last quarter?: Nautilus Biotechnology, Inc. (NASDAQ:NAUT) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.02. During the same quarter in the prior year, the company earned ($0.11) EPS.
How do I buy shares of Nautilus Biotechnology?: Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NAUT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial